UCB (OTCMKTS:UCBJF) Hits New 1-Year High - What's Next?

Key Points

• UCB SA's stock reached a new 52-week high of $224.84, significantly up from its previous closing price of $214.34.
• Morgan Stanley upgraded UCB to an "overweight" rating, indicating a positive outlook for the company's stock performance.
• The company's debt-to-equity ratio is 0.33, and it specializes in developing treatments for neurology and immunology diseases worldwide.

UCB SA (OTCMKTS:UCBJF - Get Free Report)'s share price reached a new 52-week high during trading on Wednesday . The stock traded as high as $224.84 and last traded at $224.84, with a volume of 10032 shares. The stock had previously closed at $214.34.

Analysts Set New Price Targets

Separately, Morgan Stanley raised UCB to an "overweight" rating in a report on Monday, June 23rd.

UCB Stock Performance

The firm has a 50 day moving average price of $202.79 and a 200 day moving average price of $185.78. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.19 and a quick ratio of 0.78.

About UCB

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.